Replies to post #202203 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Juno and Kite have near-term technologies only connected to 10% of the cancer market. They also dilute each other. Make that 5%. They work on leukemia and lymphoma. They do this by going after antigen(s) that make up both healthy and cancerous cells. They kill all healthy B-cells in the body. I can't impress on people enough how this is not the way it works with solid cancer. One poster here thinks Car-Ts can work on solid tumors, but they have not come close to approval. They can't attack solid tumors the same way they attack lymphoma and leukemia or they would always kill the patient. Instead, just like peptide vaccines or restricted DCVaccines, they are trying to find the right antigens and neoantigens to attack and only kill cancer cells. Just like Celldex and Immunocellular, they have not found the right cocktail of antigen(s) and neoantigen(s).

DCVax, on the other hand, has a product that can target 90% to 100% of the cancer market without artificially selecting things like killing all healthy B-cells in the body to win. Essentially, 1st and second generation Car-T's are being asked to do things the body would never do because of nature's evolutionary safety defaults. DCVax instead works within the evolutionary safety defaults.

[md1225]

Scum bags set the prices and approval process for CARTs.

George’s Soros’s wealth, Soros Fund Management, was Kite’s 11th-largest holder. It owned 2% of the company’s stock after purchasing the shares at less than $30.

Michael Milken also was an early investor in KITE as you know, that's how and why toxic dangerous CART therapies were approved.

MONEY

All good set the stage for safe efficacious DCVax.

Chris LaCoursiere

[GoodGuyBill]

Hey BSB,

When were you told L & D are the same? Was this recently or back in 2014? Curious minds want to know...

I think Juno & Kite set the benchmark for what comparable
revenue streams would be worth if we sell L.

So sell L for $8bn or maybe a lot more as Large Pharma will now know
there`s no difference between L and D other than the indications they`ve
been trialled in, but that then leaves a dilemma as to the Net Present Value of all of D`s targeted cancers if indeed by definition L can do the same job .

So..if L & D are the same and the intrinsic value for L is lets say
$8bn add the NPV of the stage 1/2 trials of D for another $8bn we could well be looking at $16bn, or $16pps

Before anyone says L & D are not the same, I was told that DIRECTLY from an officer of the company so dont bother.

[Kam8]

Hope pps $16 or above